Effect of tiotropium versus montelukast on airway inflammation and remodeling in asthma

Effect of tiotropium versus montelukast on airway inflammation and remodeling in asthma - Effect of tiotropium versus montelukast on airway inflammation and remodeling in asthma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019042

Enrollment

100

Registered

2015-09-24

Start date

2015-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma

Interventions

Tiotropium treatment group Respimat (2.5mcg) 2 inhalation once daily Treatment period 6 months Montelukast treatment group Kipres (10mg) oral once daily Treatment period 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Symptomatic asthma patients who have been treated with ICS+LABA

Exclusion criteria

Exclusion criteria: 1. Patients who have any coexisting pulmonary diseases other than asthma 2. Pregnancy or lactation 3. Patients have hypersensitivity to tiotropium or montelukast 4. Patients judged to be unsuitable by the doctors

Design outcomes

Primary

Measure	Time frame
Indices of chest CT, FeNO(baseline and after 6 months treatment)	—

Secondary

Measure	Time frame
Parameters of pulmonary function Cell counts of induced sputum Scores of quality of life	—

Countries

Japan

Contacts

Public ContactMakoto Hoshino

Atami Hospital, International University of Health and Welfare Division of Clinical Allergy, Department of Internal Medicine

hoshino@iuhw.ac.jp0557-81-9171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026